Fig. 4: Loss of ADAM12 leads to delayed tumor growth and better survival following IR in a mouse model. | Cancer Gene Therapy

Fig. 4: Loss of ADAM12 leads to delayed tumor growth and better survival following IR in a mouse model.

From: ADAM12 expression is upregulated in cancer cells upon radiation and constitutes a prognostic factor in rectal cancer patients following radiotherapy

Fig. 4

A Experimental setup of the syngeneic mouse colon cancer model, indicating the irradiation of cells prior to injection. B Growth curves of wildtype (WT) and ADAM12-knockout (A12−/−) tumors following irradiation of cancer cells with 0 Gy or 5 Gy prior injection. C Time required for the different groups to reach the tumor size endpoint. D, E Kaplan–Meier curves showing the survival of mice bearing WT or A12−/− tumors without irradiation of cancer cells prior to injection (D) or following 5 Gy irradiation of cancer cells prior to injection (E). Extra sum-of-squares F-test of exponential growth models (B), Welch’s one-way ANOVA with correction for multiple comparisons using FDR control by Benjamini, Krieger, and Yekutieli method (C) or Log-rank test (D, E) were applied to test for significant differences: *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.

Back to article page